Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Turn Therapeutics Inc. (TTRX)
USD9.66
+0.02 (+0.16%)
US NASDAQ Healthcare Biotechnology
Address
250 N Westlake Blvd 91362
Westlake Village, CA, US
Westlake Village, CA, US
CEO
Bradley E. Burnam
Website
turntherapeutics.com
IPO
2025-10-08
CIK 2023016 ISIN US90021W1053
Description
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD9.66
+0.02 (+0.16%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
43.5K
Beta
2.10
Float Shares
10.83M
Free Float %
36.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.42% | +17.37% | +68.95% | +75.41% | +81.87% | +62.94% | -8.29% | -8.29% | -8.29% | -8.29% | -8.29% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
9.66
DCF (Unlevered)
0.18
-98.1%
DCF (Levered)
0.36
-96.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-76.9% Q1'26: -24.6% (vs Q2'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -550.3% (vs Q2'24)
-
Share dilution Biotechnology: -3.4%+2.4% ★ Q1'26: +121.0% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -1.22× (vs Q2'24)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
200.0K
200.0K – 200.0K
|
2.55M
2.55M – 2.55M
+1,175.0% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
72.53M
72.53M – 72.53M
|
| EBITDA |
-5.81M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-5.86M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-3.19M
est: -1.99M (-60.3%)
|
-1.37M
-1.37M – -1.37M
+31.0% YoY
|
-2.06M
-2.06M – -2.06M
-50.0% YoY
|
-2.34M
-2.34M – -2.34M
-13.3% YoY
|
-2.47M
-2.47M – -2.47M
-5.9% YoY
|
9.48M
9.48M – 9.48M
+483.3% YoY
|
| SGA |
5.59M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.23
est: -0.15 (-58.6%)
|
-0.10
-0.10 – -0.10
+31.0% YoY
|
-0.15
-0.15 – -0.15
-50.0% YoY
|
-0.17
-0.17 – -0.17
-13.3% YoY
|
-0.18
-0.18 – -0.18
-5.9% YoY
|
0.69
0.69 – 0.69
+483.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-06-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
20
Total invested
1.48M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
20
-2 vs prev Q
New positions
3
Closed positions
5
Increased
6
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DDFG, INC | 70.5K +18.2K (+34.9%) | 225.7K +19.7K (+9.6%) | 0.51% +0.133 pp | 0.05% +0.004 pp | USD3.75 -14.7% | 2 qtrs — |
| 2 | MILLENNIUM MANAGEMENT LLC | 69.8K -25.9K (-27.1%) | 223.2K -153.5K (-40.8%) | 0.51% -0.188 pp | 0.00% 0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 3 | WELLINGTON SHIELDS & CO., LLC | 65.7K +— (+0.0%) | 210.3K -48.6K (-18.8%) | 0.48% +0.000 pp | 0.05% -0.010 pp | USD3.94 -18.8% | 2 qtrs — |
| 4 | — | 49.5K +49.5K (+100.0%) | 158.2K +158.2K (+100.0%) | 0.36% +0.360 pp | 0.00% +0.000 pp | USD3.20 +0.0% | 1 qtrs NEW |
| 5 | TAMAR SECURITIES, LLC | 30.0K +15.0K (+100.0%) | 96.0K +36.9K (+62.4%) | 0.22% +0.109 pp | 0.01% +0.004 pp | USD3.57 -10.4% | 2 qtrs — |
| 6 | BROWN BROTHERS HARRIMAN & CO | 23.7K +— (+0.0%) | 75.8K -17.5K (-18.8%) | 0.17% +0.000 pp | 0.00% 0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 7 | XTX TOPCO LTD | 19.7K -5.4K (-21.6%) | 63.1K -36.1K (-36.4%) | 0.14% -0.040 pp | 0.00% -0.002 pp | USD3.94 -18.8% | 2 qtrs — |
| 8 | HIGHTOWER ADVISORS, LLC | 19.7K +— (+0.0%) | 63.0K -14.6K (-18.8%) | 0.14% +0.000 pp | 0.00% +0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 9 | RVW WEALTH, LLC | 18.0K +— (+0.0%) | 57.6K -13.3K (-18.8%) | 0.13% +0.000 pp | 0.00% -0.001 pp | USD3.94 -18.8% | 2 qtrs — |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 17.1K +— (+0.0%) | 54.9K -12.7K (-18.8%) | 0.12% +0.000 pp | 0.00% +0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 11 | MIRACLE MILE ADVISORS, LLC | 16.0K +— (+0.0%) | 51.2K -11.8K (-18.8%) | 0.12% +0.000 pp | 0.00% 0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 12 | BANK OF AMERICA CORP /DE/ | 14.1K +— (+0.0%) | 45.2K -10.5K (-18.8%) | 0.10% +0.000 pp | 0.00% +0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 13 | LPL FINANCIAL LLC | 13.3K +300.0 (+2.3%) | 42.6K -8.7K (-16.9%) | 0.10% +0.002 pp | 0.00% +0.000 pp | USD3.92 -18.4% | 2 qtrs — |
| 14 | VANGUARD FIDUCIARY TRUST CO | 12.5K +12.5K (+100.0%) | 39.9K +39.9K (+100.0%) | 0.09% +0.091 pp | 0.00% +0.000 pp | USD3.20 +0.0% | 1 qtrs NEW |
| 15 | MORGAN STANLEY | 10.0K +— (+0.0%) | 32.0K -7.4K (-18.8%) | 0.07% +0.000 pp | 0.00% +0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 16 | HODGES CAPITAL MANAGEMENT INC. | 10.0K +— (+0.0%) | 32.0K -7.4K (-18.8%) | 0.07% +0.000 pp | 0.00% -0.001 pp | USD3.94 -18.8% | 2 qtrs — |
| 17 | RONALD BLUE TRUST, INC. | 1.1K +— (+0.0%) | 3.6K -831.0 (-18.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 18 | WELLS FARGO & COMPANY/MN | 1.0K +— (+0.0%) | 3.2K -740.0 (-18.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 19 | UBS GROUP AG | 400.00 +400.0 (+100.0%) | 1.3K +1.3K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD3.20 +0.0% | 1 qtrs NEW |
| 20 | PFLUG KOORY, LLC | 170.00 +— (+0.0%) | 544.00 -126.0 (-18.8%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD3.94 -18.8% | 2 qtrs — |
| 21 | JANE STREET GROUP, LLC | — -17.2K (-100.0%) | — -67.6K (-100.0%) | 0.00% -0.125 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 22 | TOWER RESEARCH CAPITAL LLC (TRC) | — -137.0 (-100.0%) | — -540.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 23 | ROYAL BANK OF CANADA | — -267.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 24 | CITADEL ADVISORS LLC | — -21.0K (-100.0%) | — -82.7K (-100.0%) | 0.00% -0.153 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.02% | 342.0K | 0.60% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 505.66 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 1.4K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 102.55 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 237.1K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 519.90 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 282.71 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 114.38 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 12.63 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 1.77 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
Shares Outstanding
29.79M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bradley E. Burnam | Founder, Chief Executive Officer & Director | 465.7K | male |
| Zuraiz Chaudhary | Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer | 365.3K | male |
| Mohammed Zubair | Controller | — | — |
| Neilesh Shailesh Ghodadra | Chief Medical Officer & Director | — | — |
| Stephen Hahn FASTRO | Executive Clinical & Regulatory Lead | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TTRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
